The
following table reconciles net income attributable to LifeMD, Inc. common stockholders from continuing operations and discontinued operations
to basic and diluted earnings per share:
SCHEDULE
OF BASIC AND DILUTED EARNINGS PER SHARE
| | |
2026 | | |
2025 | |
| | |
March 31, | |
| | |
2026 | | |
2025 | |
| Net loss from continuing operations | |
$ | (8,872,596 | ) | |
$ | (1,645,355 | ) |
| Less: Preferred stock dividends | |
| (776,563 | ) | |
| (776,563 | ) |
| Net loss from continuing operations attributable to LifeMD, Inc. common stockholders | |
| (9,649,159 | ) | |
| (2,421,918 | ) |
| Net income from discontinued operations | |
| - | | |
| 1,993,422 | |
| Less: Net income attributable to noncontrolling interests of discontinued operations | |
| - | | |
| 531,845 | |
| Net income from discontinued operations attributable to LifeMD, Inc. common stockholders | |
| - | | |
| 1,461,577 | |
| Net loss attributable to LifeMD, Inc. common stockholders | |
$ | (9,649,159 | ) | |
$ | (960,341 | ) |
|